Penile cancers are rare, the vast majority is represented by squamous cell carcinoma, with HPV virus being found in 30 to 40% of cases. At a locally advanced or metastatic stage, first-line treatment relies on platinum and taxane based polychemotherapy. The prognosis for advanced or metastatic penile cancer remains poor, with overall survival ranging from 13.9 to 17.1 months. After the first line, guidelines recommend various chemotherapy treatments or targeted anti-EGFR therapies whose results as well as the level of evidence are limited. A better understanding of the oncogenic pathways involved in penile cancer and a frequent expression of PD-L1 are the rationale for the elaboration of new strategies. This review article presents the data, guidelines and ongoing studies in locally advanced or metastatic penile cancer.
Bulletin du cancer. 2020 Jun [Epub]
Noémie Gassian, Alexandre Frontczak, Antoine El Kaddissi, Fabien Calcagno, Hamadi Almotlak, Johann Barkatz, Guillaume Mouillet, Tristan Maurina, Ulrich Stein, T Nguyen Tan Hon, Thibaut Murez, Antoine Thiery-Vuillemin
CHU de Besançon, oncologie, 25030 Besançon cedex, France. Electronic address: ., CHU de Besançon, urologie, 25030 Besançon cedex, France., CHU de Besançon, oncologie, 25030 Besançon cedex, France., CHU Montpellier, urologie, 34295 Montpellier, France., CHU de Besançon, oncologie, 25030 Besançon cedex, France; CHU de Besançon, oncologie, 25030 Besançon cedex, France; Inserm, UMR1098, 25020 Besançon cedex, France.